登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C25H30N2O5 · HCl
化学文摘社编号:
分子量:
474.98
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
Quinapril hydrochloride, ≥98% (HPLC), solid
InChI key
IBBLRJGOOANPTQ-JKVLGAQCSA-N
SMILES string
Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3ccccc3C[C@H]2C(O)=O
InChI
1S/C25H30N2O5.ClH/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30;/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30);1H/t17-,21-,22-;/m0./s1
assay
≥98% (HPLC)
form
solid
color
white
solubility
H2O: >10 mg/mL
storage temp.
2-8°C
Quality Level
Gene Information
human ... ACE(1636)
正在寻找类似产品? 访问 产品对比指南
Application
Quinapril hydrochloride has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on renal tubular epithelial cell proliferation in human renal tubular epithelial cells. It has also been used as an ACE inhibitor to evaluate its effects on the expression of angiotensin II (AII) in patient-derived Atheroma samples.
Biochem/physiol Actions
Quinapril has been studied to exhibit therapeutic effects against hypertension and congestive heart failure.
Quinapril is a short-acting angiotensin converting enzyme (ACE) inhibitor.
signalword
Danger
hcodes
Hazard Classifications
Repr. 2 - STOT RE 1
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
A M D Watson et al.
Diabetologia, 53(1), 192-203 (2009-10-29)
There is convincing evidence that the endothelin system contributes to diabetic nephropathy and cardiovascular disease. This study aimed to assess the effects of the non-peptidergic endothelin receptor A (ETA) antagonist avosentan in a mouse model of accelerated diabetic nephropathy and
B Daan Westenbrink et al.
Heart (British Cardiac Society), 97(19), 1590-1596 (2011-07-16)
To investigate the association between sustained postoperative anaemia and outcome after coronary artery bypass graft (CABG) surgery. Retrospective analysis of the IMAGINE trial, which tested the effect of the ACE inhibitor quinapril on cardiovascular events after CABG. Thoracic surgery clinic/outpatient
Spyridon Deftereos et al.
The American journal of cardiology, 105(1), 54-58 (2010-01-28)
Angiotensin-converting enzyme inhibitors have been reported to inhibit in-stent restenosis. To assess the effect of angiotensin-converting enzyme inhibition on in-stent restenosis and its relation to apoptosis, 86 patients with chronic coronary artery disease who required stent implantation in the left
Syed T Rahman et al.
Journal of cardiovascular pharmacology and therapeutics, 17(2), 139-145 (2011-07-14)
We sought to determine whether a combination of angiotensin-converting enzyme inhibitors (ACEIs) and the nutraceutical α-lipoic acid (ALA) regulates blood pressure, endothelial function, and proteinuria in diabetic patients with Stage I hypertension. A total of 40 diabetic patients with Stage
Christine R Culy et al.
Drugs, 62(2), 339-385 (2002-01-31)
Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor. Quinapril produces favourable haemodynamic changes, and improves ventricular and endothelial function in patients with various cardiovascular disorders; these effects are mediated
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持